With $26M Series D, Antibody Platform Developer Sutro Biopharma To Prep Its Own Products
This article was originally published in The Pink Sheet Daily
Executive Summary
The decade-old San Francisco antibody developer previously has relied on platform partnerships, but now will attempt to bring a candidate – likely a bi-specific antibody – into the clinic within 18 months. Six investors, including three corporate VCs, composed the returning syndicate.